Trial NC-HEM-07-7

A Phase I/II Study of Immunotherapy with Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients with Chronic Immune Thrombocytopenic Purpura.

Type: Non-Cancer Related; Therapeutic
Phase: Phase I/II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Howard Liebman, M.D.
Other Trial Staff: Laurie Hornor, R.N., Melissa Peralta, D.M.

Staff may log in to see study documents.

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.